The study demonstrated that Chrysalin extensively decreases myocardial injury when administered following a major ischemic insult. Endpoints of the study included infarct size, coronary microvessel function, myocardial function and apoptotic markers.
Randolph Steer, president of OrthoLogic, said: “While studies have been performed incorporating models with normal cholesterol levels, to our knowledge no one has reported on the effects of putative cardioprotective drugs using this more challenging model of hypercholesterolemia with endothelial dysfunction.
“This model is the closest parallel to the human clinical condition of acute cardiac distress, and we believe Chrysalin is the only drug candidate ever to report effectiveness.”